HOOK
NASDAQHOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. (HOOK) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for HOOK in the last 30 days. The most recent was published Mar 26, 2026.
Latest news
25 items- PRHOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail TherapeuticsNEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the completion of the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. ("NeoTrail"). The purchase price remains undisclosed. The asset purchase agreement was signed on January 28, 2026, and the closing of the transaction occurred on March 20, 2026. About HB-200 Eseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. HB-200 alternates the administration of both HB-201 (LCMV) and HB-202 (PIC
- PRHOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail TherapeuticsNEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. ("NeoTrail"). The purchase price remains undisclosed. "We are delighted that the clinical development of these promising therapeutics will continue at NeoTrail with an opportunity to deliver patient benefit in multiple major market indications," stated Mark Winderlich, Chief R&D Officer of HOOKIPA. The asset purchase agreement was signed on January 28, 2026, and the transaction is expected to c
- PRHOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to GileadNEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets related to HOOKIPA's HB-500 program to Gilead Sciences, Inc. ("Gilead"). In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement ("Asset Purchase Agreement") with Gilead pursuant to which Gilead agreed to acquire all of HOOKIPA's assets primarily related to or necessary for the conduct of HOOKIPA's HB-400 program, currently in clinica
- INSIDERChief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
- SECSEC Form 15-12G filed by HOOKIPA Pharma Inc.15-12G - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form EFFECT filed by HOOKIPA Pharma Inc.EFFECT - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form EFFECT filed by HOOKIPA Pharma Inc.EFFECT - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form 25 filed by HOOKIPA Pharma Inc.25 - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form S-8 POS filed by HOOKIPA Pharma Inc.S-8 POS - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form S-8 POS filed by HOOKIPA Pharma Inc.S-8 POS - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form S-8 POS filed by HOOKIPA Pharma Inc.S-8 POS - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form S-8 POS filed by HOOKIPA Pharma Inc.S-8 POS - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form POS AM filed by HOOKIPA Pharma Inc.POS AM - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form POS AM filed by HOOKIPA Pharma Inc.POS AM - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECHOOKIPA Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
- INSIDERChief Executive Officer Peters Malte sold $26,842 worth of shares (29,176 units at $0.92), decreasing direct ownership by 27% to 79,519 units (SEC Form 4)4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
- INSIDEREVP and CFO Coelho Mary Theresa sold $12,520 worth of shares (13,609 units at $0.92), decreasing direct ownership by 19% to 56,266 units (SEC Form 4)4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)
- SECHOOKIPA Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
- PRHOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common StockNEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market ("Nasdaq") and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of dire
- SECSEC Form DEFM14A filed by HOOKIPA Pharma Inc.DEFM14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form PRER14A filed by HOOKIPA Pharma Inc.PRER14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form PREM14A filed by HOOKIPA Pharma Inc.PREM14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form DEFA14A filed by HOOKIPA Pharma Inc.DEFA14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECSEC Form DEFA14A filed by HOOKIPA Pharma Inc.DEFA14A - HOOKIPA Pharma Inc. (0001760542) (Filer)
- SECHOOKIPA Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)
HOOK FAQ
8 questionsWhat does HOOKIPA Pharma Inc. do?
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead...What is the latest news on HOOK?
Quantisnow has not tracked any new filings, ratings or press releases for HOOK in the last 30 days. The most recent wire item was published on March 26, 2026.Where does HOOK stock trade?
HOOKIPA Pharma Inc. (HOOK) is listed on NASDAQ.What sector and industry is HOOK in?
HOOKIPA Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did HOOKIPA Pharma Inc. go public?
HOOKIPA Pharma Inc. (HOOK) completed its IPO in 2019.What are analysts saying about HOOK?
Across the last 8 analyst actions on HOOKIPA Pharma Inc., there were 0 upgrades and 3 downgrades. The most recent action was from RBC Capital Mkts: Sector Perform with a $2.00 price target on 2024-12-20.What companies are similar to HOOK?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare HOOK side-by-side with any of them on Quantisnow.How can I track HOOK on Quantisnow?
Quantisnow aggregates HOOKIPA Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HOOK to receive live email and push alerts on every new disclosure.